【#瑞士对微软365办公软件涨价展开调查#】#微软回应瑞士调查365办公软件涨价#综合多家外媒报道， 瑞士竞争委员会15日宣布，对美国微软公司启动初步调查，以评估微软365办公软件套装涨价行为是否 违反了瑞士市场竞争相关法规。瑞士竞争委员会15日发布声明说，他们近期收到来自多个企业和政府机 构的投诉，反对微软365办公软件套装涨价。瑞士竞争委员会指出，他们将判断微软是否违反瑞士相关 市场竞争法规，并考虑让价格监督机构参与评估，具体措施将取决于初步调查结果。一旦发现违法迹 象，将启动对微软的正式调查。微软方面当天则回应称，将配合瑞士竞争委员会的调查工作。 (央视财 经) ...

Core Viewpoint - The company is expected to report significant losses in 2025 due to impairment related to its investment in French HCo, but operational performance is projected to improve substantially when excluding this factor [1][2] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of between -356 million yuan and -178 million yuan for 2025 [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -376 million yuan and -198 million yuan [1] - In contrast, when excluding the impact of the impairment, the company expects a net profit attributable to shareholders of between 260 million yuan and 318 million yuan for 2025 [1] Group 2: Revenue Expectations - The company forecasts an operating revenue of approximately 6.35 billion yuan for 2025, indicating a year-on-year decline [2] - However, when excluding the impact of the impairment on the investment in French HCo, the company expects a year-on-year net profit growth of 374% to 480% for 2025 [2] - The projected growth for the net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated to be between 705% and 899% year-on-year [2]

Group 1 - The chairman of the company, Peng Zhihui, has never participated in research and development activities, focusing instead on strategic decision-making and external communication [1] - The company has established a clear and independent research management system, with the co-CEO and CTO, Zhou Bin, fully responsible for all R&D projects [1] - The company aims to avoid any potential misunderstandings regarding Peng's dual roles by adhering to prudent principles in external communications and ensuring compliance with corporate governance requirements [1] Group 2 - The company has formed a research and development team for embodied intelligent robots, focusing on technology research and development for personal and family scenarios [2] - The products currently showcased are prototypes in the research phase, and this project does not alter the company's core business structure centered on new materials [2] - The initiative is considered a preliminary exploration of future possibilities and does not constitute a significant adjustment to the main business [2]

Core Viewpoint - SAIC-GM-Wuling's Huajing may evolve from a product series under the Baojun brand to an independent brand in the future [1] Group 1 - The first flagship model, Huajing S, developed in deep strategic cooperation with Huawei, is set to officially launch in the second quarter of 2026 [1]

Core Viewpoint - Jin Xing Beer is accelerating its capitalization process by applying for a listing on the Hong Kong Stock Exchange, aiming to become the first "Chinese craft beer" stock in Hong Kong [1] Company Overview - Founded in 1982, Jin Xing Beer has established 15 production bases across 9 provinces in China, with an annual production capacity of 2 million tons [1] - The company’s main products include various series of Chinese craft beer, including "Jin Xing Mao Jian," which combines tea with brewing techniques, and has expanded to flavors like jasmine tea and sugar orange [1] Financial Performance - Jin Xing Beer reported revenues of 356 million RMB, 730 million RMB, and 1.11 billion RMB for the years 2023, 2024, and the first three quarters of 2025, respectively [2][3] - The profit and total comprehensive income for the same periods were 12.2 million RMB, 125 million RMB, and 305 million RMB, with gross margins increasing from 27.3% to 47.0% [2] Product Contribution - In 2024, the revenue from Chinese craft beer reached 377 million RMB, accounting for 51.7% of total revenue, which increased to 867 million RMB and 78.1% in the first nine months of 2025 [4] - Other product categories, such as the 1982 original beer and new generation beer, saw significant revenue declines of 19.0% and 44.7%, respectively [4] Dividend Policy - Prior to its IPO, Jin Xing Beer has implemented substantial dividends, distributing a total of 329 million RMB to shareholders, exceeding its net profit for the first nine months of 2025 [4] Ownership Structure - The company exhibits a family-controlled ownership structure, with the founder and his son controlling 93.45% of the shares [4] Industry Growth - The craft beer market in China is in an expansion phase, with a compound annual growth rate (CAGR) of 38.4% from 2019 to 2024, projected to reach a market size of 182.1 billion RMB by 2029 [5] - The flavored craft beer segment is expected to grow from 11.1 billion RMB in 2024 to 66 billion RMB by 2029, with a CAGR of 42.8% [5] Fundraising Purpose - Jin Xing Beer plans to use the proceeds from its IPO to enhance production capacity, strengthen sales networks, marketing activities, product innovation, and improve digital capabilities [6]

Core Viewpoint - FAW Audi has achieved a significant milestone of reaching 10 million users, becoming the first joint venture luxury car brand in China to do so, reflecting its deep integration into China's reform and opening-up process and its commitment to Sino-German automotive cooperation [3][4]. Group 1: Milestone Celebration - The "10 Million Users Celebration and New Product Launch Night" was held in Shenzhen, marking FAW Audi's 38 years of development and its new customer experience strategy "Zhen·Heart Path" aimed at providing high-quality luxury experiences [1][4]. - The event featured the global debut of the new Audi A6L and the launch of the new Audi Q5L, which is the first luxury fuel SUV equipped with Huawei's Qian Kun intelligent driving technology [1][5]. Group 2: Historical Achievements - FAW Audi has been a pioneer in the Chinese luxury car market, introducing several industry firsts, such as the extended Audi A6 in 1999 and the 4S sales service system in 2000, which set a benchmark for luxury car services [4]. - The introduction of the domestically produced Audi Q5 in 2010 successfully tapped into the domestic B-class luxury SUV market, showcasing FAW Audi's alignment with consumer demands [4]. Group 3: Future Strategy and Product Development - FAW Audi is set to launch several key models, including the new Audi Q5L and Audi A6L e-tron by 2026, as part of its strategy to embrace the era of luxury intelligent mobility [5][8]. - The company aims to achieve a second "10 million" milestone by focusing on the luxury automotive market and enhancing its product offerings through innovative platforms for both fuel and electric vehicles [8][9]. Group 4: Product Features and Innovations - The new Audi Q5L features a 125mm longer wheelbase compared to its overseas version and offers three exclusive color options for the Chinese market [9]. - It is equipped with the fifth-generation EA888 engine and HDI dual-motor hybrid technology, achieving a 15% reduction in fuel consumption compared to the previous generation [9]. - The vehicle also includes Huawei's customized Qian Kun intelligent driving technology, enhancing its multi-scenario driving assistance capabilities [9].

作者丨彭鑫 编辑丨安安 当地时间1月15日，马斯克在社交平台上回应网友时表示，在大约3年内，星舰将每小时发射不止一次。 该网友晚些时候评论称："星舰三年内飞行次数可能超过每小时一次，这意味着每年飞行近万次！按100 吨的有效载荷能力计算，每年可运送100万吨货物，这大约是人类太空飞行史上总运载量的20倍。简直 太疯狂了！"马斯克回应称："可能需要四年时间，但不会超过四年。" ...

编辑丨安安 作者丨彭鑫 继京东之后，又一互联网平台美团切入汽车销售领域。2026年1月15日，上海喜车未来智能科技有限公 司与美团在上海签署战略合作协议。双方将整合汽车产业与本地生活服务优势，共同构建"买车用车 +本地生活"一站式服务平台。（新浪财经） ...

Group 1: WuXi AppTec - WuXi AppTec expects a net profit of approximately RMB 19.15 billion for the year 2025, representing a year-on-year growth of about 102.6% [1] - The company anticipates total revenue of around RMB 45.46 billion for 2025, reflecting a year-on-year increase of approximately 15.8%, with a 21.4% growth in revenue from continuing operations [1] - Basic earnings per share are projected to be around RMB 6.70, which is an increase of approximately 104.3% compared to the previous year [1] Group 2: Rongchang Biologics - Rongchang Biologics has signed an exclusive licensing agreement with AbbVie for RC148, granting AbbVie exclusive rights for development, production, and commercialization outside Greater China [2] - The agreement includes an upfront payment of USD 650 million and potential milestone payments up to USD 4.95 billion, along with double-digit royalties on net sales outside Greater China [2] - This licensing deal is expected to accelerate the global development and commercialization of RC148, enhancing the company's brand value and international influence [2] Group 3: National Medical Insurance Administration - The sixth batch of centralized procurement for high-value medical consumables has been conducted, with 202 out of 496 products winning bids, ensuring a diverse supply of mainstream products [3][4] - The procurement process emphasizes principles such as maintaining clinical stability, ensuring quality, and preventing price undercutting, with a focus on grouping products based on clinical demand [4] - The procurement includes drug-coated balloons and urological intervention consumables, with all 42 products from 32 companies in the drug-coated balloon category winning bids [3][4] Group 4: New Drug Listings and Market Expansion - As of January 11, over 11,000 designated medical institutions have equipped new drugs added to the medical insurance directory for 2025, including 105 negotiated drugs and 19 commercial insurance innovative drugs [5][6] - Among the 105 new negotiated drugs, 88 have available institution information, with significant coverage across provinces, indicating a strong distribution network [6] - The approval of insulin glargine injection by the European Commission marks a significant entry for Gan Li Pharmaceutical into the European market [7] Group 5: WuXi Biologics - WuXi Biologics' subsidiary, WuXi HeLian, has made a conditional cash offer to acquire all issued shares of Dongyao Pharmaceutical at HKD 4 per share, representing a premium of approximately 99% over the last undisturbed closing price [8] - The total consideration for the acquisition could reach approximately HKD 3.1047 billion, with the offer contingent on obtaining at least 60% of the voting rights [8] - This acquisition aims to expand production capacity and enhance the project and client portfolio in the ADC CDMO sector [8] Group 6: Sanofi Biologics - Sanofi Biologics expects a net profit for 2025 to be between RMB 152 million and RMB 190 million, indicating a year-on-year growth of 204.42% to 280.53% [9] - The projected net profit excluding non-recurring gains is expected to be between RMB 149 million and RMB 186 million, reflecting a significant increase compared to the previous year [9] - The growth is attributed to the company's strategic focus on expanding production capacity and increasing market demand for peptide raw materials [9]

Core Viewpoint - The recent market for pig iron is showing a stable yet slightly strengthening trend, with prices increasing marginally due to limited supply pressure and improved market sentiment [1] Price Trends - As of January 16, the average daily price of pig iron in China is 2687.73 yuan per ton, reflecting a week-on-week increase of 0.24% [1] Supply and Demand Dynamics - Supply pressure remains low, with some coking enterprises testing price increases, while coke prices have stabilized [1] - However, the upcoming holiday period is expected to dampen demand, leading to a cautious outlook for the short-term pig iron market [1] Market Sentiment - Overall market sentiment is improving, but the anticipated holiday may pose challenges for demand sustainability [1]